Vital Therapies, Inc. (VTL) Reaches $5.80 After 5.00% Down Move; Last Week Insulet (PODD) Analysts

December 27, 2017 - By Dolores Ford

Among 16 analysts covering Insulet Corporation (NASDAQ:PODD), 11 have Buy rating, 1 Sell and 4 Hold. Therefore 69% are positive. Insulet Corporation had 42 analyst reports since July 29, 2015 according to SRatingsIntel. The company was maintained on Friday, November 6 by Northland Capital. The stock of Insulet Corporation (NASDAQ:PODD) has “Hold” rating given on Friday, August 4 by Oppenheimer. Jefferies maintained Insulet Corporation (NASDAQ:PODD) rating on Wednesday, September 27. Jefferies has “Buy” rating and $58.0 target. The firm has “Hold” rating by Canaccord Genuity given on Tuesday, August 22. The firm has “Hold” rating by Canaccord Genuity given on Monday, July 10. Jefferies maintained Insulet Corporation (NASDAQ:PODD) rating on Thursday, August 4. Jefferies has “Buy” rating and $45 target. The stock of Insulet Corporation (NASDAQ:PODD) has “Equal-Weight” rating given on Monday, November 2 by Morgan Stanley. Jefferies maintained the shares of PODD in report on Thursday, August 3 with “Buy” rating. Jefferies maintained the shares of PODD in report on Friday, November 3 with “Buy” rating. Robert W. Baird maintained Insulet Corporation (NASDAQ:PODD) rating on Friday, October 13. Robert W. Baird has “Buy” rating and $65.0 target. See Insulet Corporation (NASDAQ:PODD) latest ratings:

20/12/2017 Broker: Cowen & Co Rating: Buy New Target: $80.0 Maintain
20/11/2017 Broker: Barclays Capital Rating: Overweight Old Target: $70 New Target: $75 Maintain
03/11/2017 Broker: Morgan Stanley Rating: Equal-Weight Old Target: $55 New Target: $63 Maintain
03/11/2017 Broker: Robert W. Baird Rating: Outperform Old Target: $65 New Target: $72 Maintain
03/11/2017 Broker: Jefferies Rating: Buy New Target: $67.0 Maintain
03/11/2017 Broker: Canaccord Genuity Old Rating: Hold New Rating: Buy Upgrade
13/10/2017 Broker: Robert W. Baird Rating: Buy New Target: $65.0 Maintain
12/10/2017 Broker: Leerink Swann Rating: Buy New Target: $74.0 Maintain
10/10/2017 Broker: Wedbush Rating: Buy New Target: $65.0 Maintain
05/10/2017 Broker: Piper Jaffray Rating: Buy New Target: $58.0 Maintain

The stock of Vital Therapies, Inc. (NASDAQ:VTL) is a huge mover today! The stock decreased 4.13% or $0.25 during the last trading session, reaching $5.8. About 62,301 shares traded. Vital Therapies, Inc. (NASDAQ:VTL) has declined 61.75% since December 27, 2016 and is downtrending. It has underperformed by 78.45% the S&P500.The move comes after 8 months negative chart setup for the $244.80M company. It was reported on Dec, 27 by Barchart.com. We have $5.51 PT which if reached, will make NASDAQ:VTL worth $12.24 million less.

Since December 12, 2017, it had 1 buy, and 0 insider sales for $548,335 activity. Satter Muneer A bought $548,335 worth of Vital Therapies, Inc. (NASDAQ:VTL) on Tuesday, December 12.

Investors sentiment increased to 0.82 in 2017 Q3. Its up 0.06, from 0.76 in 2017Q2. It improved, as 8 investors sold Vital Therapies, Inc. shares while 14 reduced holdings. 8 funds opened positions while 10 raised stakes. 9.66 million shares or 5.18% less from 10.19 million shares in 2017Q2 were reported. State Common Retirement Fund reported 0% of its portfolio in Vital Therapies, Inc. (NASDAQ:VTL). Bancorp Of America Corp De has 0% invested in Vital Therapies, Inc. (NASDAQ:VTL) for 2,550 shares. Deutsche Financial Bank Ag reported 0% in Vital Therapies, Inc. (NASDAQ:VTL). Bnp Paribas Arbitrage Sa holds 0% or 939 shares. Vanguard Group stated it has 0% in Vital Therapies, Inc. (NASDAQ:VTL). Blair William Il has invested 0% in Vital Therapies, Inc. (NASDAQ:VTL). National Bank Of New York Mellon Corp holds 25,163 shares. Element Capital Mgmt Limited Liability Company reported 35,463 shares. 2.60M were reported by Victory Cap Mgmt. Group One Trading L P invested in 0% or 2,000 shares. Balasa Dinverno And Foltz Limited Com holds 0.02% or 24,575 shares. Royal Natl Bank Of Canada holds 6 shares or 0% of its portfolio. 10,000 were accumulated by Hightower Advsr Ltd. Goldman Sachs Inc invested in 0% or 12,717 shares. Jpmorgan Chase & Com holds 0% of its portfolio in Vital Therapies, Inc. (NASDAQ:VTL) for 25,462 shares.

Analysts await Vital Therapies, Inc. (NASDAQ:VTL) to report earnings on March, 6. They expect $-0.30 EPS, up 18.92% or $0.07 from last year’s $-0.37 per share. After $-0.30 actual EPS reported by Vital Therapies, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Among 7 analysts covering Vital Therapies Inc (NASDAQ:VTL), 3 have Buy rating, 0 Sell and 4 Hold. Therefore 43% are positive. Vital Therapies Inc has $23 highest and $5 lowest target. $10.20’s average target is 75.86% above currents $5.8 stock price. Vital Therapies Inc had 12 analyst reports since August 7, 2015 according to SRatingsIntel. Canaccord Genuity maintained it with “Buy” rating and $8.0 target in Monday, August 24 report. The firm has “Buy” rating by SunTrust given on Monday, August 24. Credit Suisse downgraded it to “Neutral” rating and $9 target in Monday, August 24 report. The company was downgraded on Monday, October 26 by BTIG Research. The rating was initiated by BTIG Research on Friday, August 7 with “Buy”. The stock of Vital Therapies, Inc. (NASDAQ:VTL) earned “Outperform” rating by Credit Suisse on Monday, August 10. Suntrust Robinson downgraded Vital Therapies, Inc. (NASDAQ:VTL) on Monday, August 24 to “Neutral” rating. Suntrust Robinson downgraded Vital Therapies, Inc. (NASDAQ:VTL) on Tuesday, September 29 to “Neutral” rating. On Monday, August 24 the stock rating was downgraded by William Blair to “Outperform”. The firm has “Neutral” rating given on Tuesday, September 29 by SunTrust.

Vital Therapies, Inc., a biotherapeutic company, focuses on developing a human hepatic cell therapy targeting the treatment of acute forms of liver failure in the United States. The company has market cap of $244.80 million. The Company’s ELAD system is an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials to allow the patientÂ’s own liver to potentially regenerate to a healthy state or to stabilize the patient until transplant. It currently has negative earnings. The firm was formerly known as Vitagen Acquisition Corp. and changed its name to Vital Therapies, Inc. in June 2003.

Investors sentiment decreased to 1.1 in Q3 2017. Its down 0.10, from 1.2 in 2017Q2. It dived, as 14 investors sold Insulet Corporation shares while 55 reduced holdings. 31 funds opened positions while 45 raised stakes. 60.96 million shares or 0.49% less from 61.26 million shares in 2017Q2 were reported. Price T Rowe Md accumulated 0% or 30,904 shares. Aqr Mgmt Lc invested 0% of its portfolio in Insulet Corporation (NASDAQ:PODD). Shaker Investments Limited Liability Company Oh has invested 3.09% in Insulet Corporation (NASDAQ:PODD). Guggenheim Cap Llc accumulated 9,196 shares. Eulav Asset Mgmt invested in 0.05% or 19,800 shares. X Mgmt Ltd Liability invested in 0% or 425 shares. Fmr, a Massachusetts-based fund reported 8.25 million shares. C Worldwide Grp Holding A S holds 0.08% or 101,083 shares in its portfolio. 4,774 were reported by Teacher Retirement Of Texas. Citigroup Inc has invested 0% of its portfolio in Insulet Corporation (NASDAQ:PODD). Macquarie Gp has invested 0% of its portfolio in Insulet Corporation (NASDAQ:PODD). Old Natl Comml Bank In owns 5,337 shares. Bnp Paribas Arbitrage has invested 0% in Insulet Corporation (NASDAQ:PODD). Federated Investors Pa, Pennsylvania-based fund reported 210,800 shares. Deutsche Retail Bank Ag reported 0.01% stake.

The stock decreased 0.75% or $0.52 during the last trading session, reaching $68.82. About 81,570 shares traded. Insulet Corporation (NASDAQ:PODD) has risen 48.83% since December 27, 2016 and is uptrending. It has outperformed by 32.13% the S&P500.